Review highlights IRAK-M's immunomodulatory role in lung disorders and its potential as a therapeutic target.
Respiratory system diseases, including infections, inflammation, fibrosis, cancer, and others, impose a substantial burden on human health worldwide. The respiratory tract is constantly exposed to external stimuli due to its connection with the outside environment. Therefore, the immune system plays a crucial role in respiratory diseases. Toll-like receptors (TLRs) recognize pathogens and initiate immune responses, serving as the first line of host defense against external pathogen invasion. Interleukin-1 receptor-associated kinases (IRAKs) are a group of kinases that mediate activation signals from TLRs and the interleukin-1 receptor (IL-1R). Among the four distinct IRAK family members, interleukin-1 receptor-associated kinase M (IRAK-M) uniquely functions as a pseudokinase and serves as a critical negative regulator of TLR/IL-1R signaling pathways, mediating diverse immunomodulatory effects in various pulmonary diseases. This review focuses on recent advancements in understanding the role of IRAK-M in lung disorders, aiming to provide a basis for future investigations into the pathogenesis and potential therapeutic targets for such conditions.
No takes yet. Share an insight, caveat, or question.
Zhai et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: